Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

Personalized Medicine and Genomics

By June 22, 2010December 5th, 2023Awareness

Last week there were several interesting articles on personalized medicine that are of interest to the NF community.

The NY Times published a two part series headlined A Decade Later, Genetic Map Yields Few New Curesby Nicholas Wade, and Awaiting the Gene Payoffby Andrew Pollack.

It is difficult to argue that the expected benefits from  the Human Genome Project  have  met projections  made at the time of the projects completion in 2000.  In hindsight these expectations look overly optimistic.  However, as we look at the research landscape today and all the work that is being done, I can’t help but borrow the baseball metaphor that we are only in the second inning.

Evidence of this is an article in Wired magazine about an announcment expected this Thursday of a joint project between 23andMme, the Michael J. Fox Foundation and the Parkinson’s Institute and Clinical Center to enroll up to 10,000 people with Parkinson’s Disease, get them genotyped using the 23andMe platform, and collect  phenotypic information. It is a long stated goal of the Children’s Tumor Foundation to establish a patient registry and bio bank that will bring these capabilities to the NF patient and research community.  While we are not in a position to announce anything today, it is an area of key interest.  More to come…

Close Menu